BioBoss host John Simboli speaks with Stefan König , CEO of George Medicines, headquartered in London. Hear Stefan’s thoughts about leadership in biopharma and how George Medicines is working to extend and improve the lives of people suffering from the world’s leading causes of death and disability—including hypertension, cardiovascular disease and type 2 diabetes

Derek Maetzold, CEO of Castle Biosciences shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Castle is leveraging its expertise in cancer genomics and the use of artificial intelligence to improve patient outcomes.

Bob Cobuzzi, Chief Executive Officer of Diffusion Pharmaceuticals,speaks with BioBoss John Simboli about leadership and how Diffusion Pharmaceuticals is working to develop novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.

Panna Sharma, CEO of Lantern Pharma, headquartered in Dallas, Texas, shares his thoughts with BioBoss host John Simboli about leadership and how Lantern is working at the intersection of artificial intelligence, genomics and machine learning to advance precision oncology therapies.

Nandan Padukone, CEO of IM Therapeutics, headquartered in Woburn, Massachusetts, shares his thoughts with BioBoss host John Simboli about leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutic design directed at human leukocyte antigens.

"I think I've always found motivation from being able to take a highly technical topic and dig in. I'm never the person that knows most about the topic. But I strive to be like the person who knows third or fourth most about whatever topic is going." 

– Mathew Gline: CEO of Roivant Sciences

Koen De Witte, managing director of reMYND NV, headquartered in Leuven, Belgium, shares his thoughts with BioBoss host John Simboli about leadership and how reMYND is advancing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. 

Lanny Sun, co-founder of Silicon Therapeutics, recently acquired by Roivant Sciences. speaks with corporate branding veteran John Simboli about leadership in biopharma. Lanny also discusses how Silicon Therapeutics, now part of Roivant Drug Discovery, is advancing its chip-to-clinic, computational quantum physics-based approach to pioneer a new path for drug design of  medicines to improve the lives of patients

Joan Perelló, co-founder and CEO of Sanifit, shares his thoughts with BioBoss host John Simboli about leadership and how Sanifit is pursuing the development of treatments for progressive vascular calcification disorders.

Saiid Zarrabian, President and CEO of Kintara Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership and how Kintara is pursuing the development of new cancer therapies for patients with rare unmet medical needs.